Growth Metrics

Merck (MRK) EBIT Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 81.11%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 3.64%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 12.96%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -203.67%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 11.54%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 14.90%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 2.04%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -42.48%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -203.67%
Dec 31, 2025 -79.57%
Sep 30, 2025 117.11%
Jun 30, 2025 74.58%
Mar 31, 2025 89.32%
Dec 31, 2024 113.79%
Sep 30, 2024 -82.34%
Jun 30, 2024 53.69%
Mar 31, 2024 129.24%
Dec 31, 2023 7.69%
Sep 30, 2023 85.83%
Jun 30, 2023 -1,059.74%
Mar 31, 2023 -36.17%
Dec 31, 2022 50.72%
Sep 30, 2022 40.22%
Jun 30, 2022 57.52%
Mar 31, 2022 -232.02%
Dec 31, 2021 27.06%
Sep 30, 2021 57.45%
Jun 30, 2021 -1.38%
Mar 31, 2021 51.33%
Dec 31, 2020 -69.29%
Sep 30, 2020 53.77%
Jun 30, 2020 79.31%
Mar 31, 2020 35.77%
Dec 31, 2019 13.96%
Sep 30, 2019 -46.55%
Jun 30, 2019 59.09%
Mar 31, 2019 26.15%
Dec 31, 2018 39.11%
Sep 30, 2018 11.23%
Jun 30, 2018 23.28%
Mar 31, 2018 5.63%
Dec 31, 2017 -29.93%
Sep 30, 2017 -4.37%
Jun 30, 2017 39.13%
Mar 31, 2017 16.74%
Dec 31, 2016 -12.59%
Sep 30, 2016 41.29%
Jun 30, 2016 11.96%
Mar 31, 2016 6.84%
Dec 31, 2015 -2.40%
Sep 30, 2015 10.76%
Jun 30, 2015 -27.20%
Mar 31, 2015 -12.66%
Dec 31, 2014 72.21%
Sep 30, 2014 -10.97%
Jun 30, 2014 -4.75%
Mar 31, 2014 8.04%
Dec 31, 2013 13.03%
Sep 30, 2013 11.28%
Jun 30, 2013 2.79%
Mar 31, 2013 -79.00%
Dec 31, 2012 -17.90%
Sep 30, 2012 -47.38%
Jun 30, 2012 -44.78%
Mar 31, 2012 -49.69%